nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-230-10-195-205nogr-3018Research ArticleОБЗОРREVIEWПрепарат меда в комплексной терапии метаболически ассоциированной жировой болезни печениHoney preparation in complex therapy of metabolically associated fatty liver diseaseБарановскийА. Ю.GomonovaV. P.noemail@neicon.ruhttps://orcid.org/0000-0001-8159-9745ГомоноваВ. П.BaranovskyA. Yu.noemail@neicon.ruhttps://orcid.org/0000-0002-1070-7697СакеянИ. С.SakeianI. S.smart.ina@mail.ruМедицинский институт ФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияSt. Petersburg State UniversityRussian Federation202410122024010195205Copyright © Барановский А.Ю., Гомонова В.П., Сакеян И.С., 20242024Барановский А.Ю., Гомонова В.П., Сакеян И.С.Gomonova V.P., Baranovsky A.Y., Sakeian I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/3018

Цель. Оценка клинической эффективности препарата меда натурального Метроп ГП у пациентов с метаболически ассоциированной жировой болезнью печени (МАЖБП). Материалы и методы. Проведено проспективное рандомизированное открытое мультицентровое исследование. Включено 70 пациентов в возрасте от 39 до 55 лет с установленным диагнозом МАЖБП. Группу исследования составили 40 человек, группу контроля - 30 человек. Все пациенты получали медикаментозную терапию гепатотропным препаратом S-адеметионином. Пациентам группы исследования также был назначен 10-дневный курс терапии Метроп ГП. Для детальной оценки влияния препарата меда все обследуемые были разделены на подгруппы в зависимости от генеза МАЖБП: ожирение/сахарный диабет 2 типа (СД 2)/метаболический синдром (МС). Оценивалась динамика жалоб. Изучалось влияние Метроп ГП на биохимические показатели крови (показатели цитолиза и холестаза, углеводный и липидный обмен) и маркеры окислительного стресса. Динамика всех показателей оценивалась дважды (до исследования и через 2 недели после 10-дневного курса лечения Метроп ГП). Неинвазивная оценка стеатоза и фиброза печени выполнялась с помощью серологического теста ФиброМакс однократно до начала терапии. Исследование было одобрено этическим комитетом ООО «Юнион Клиник» (г. Санкт-Петербург). Протокол № 1-06/2023 от 6 июня 2023 г. Все больные группы исследования подписывали добровольное информированное согласие на проведение исследования. Статистическая обработка результатов проведена с помощью SPSS 26 для Windows. Различия признавались достоверными при уровне значимости р<0,05 (95%). Результаты исследования. Согласно полученным результатам по завершении исследования, у пациентов, получающих дополнительно в составе комплексной терапии Метроп ГП продемонстрировано статистически значимое улучшение лабораторных показателей цитолитического синдрома, липидного обмена и антиоксидантного статуса, чего не было достигнуто в подгруппах сравнения. У пациентов с МАЖБП и СД 2 на фоне исследуемой терапии также наблюдалось достоверное снижение уровня глюкозы, в отличие от подгруппы контроля. Пациенты из всех исследуемых групп отмечали улучшение общего самочувствия, уменьшение диспептических явлений, однако без достоверных различий между ними. Отмечалась хорошая переносимость исследуемого препарата. Вывод. Добавление к терапии МАЖБП гепатопротектора Метроп ГП приводит к улучшению показателей липидного обмена, нормализации показателей цитолиза и антиоксидантной системы организма

The aim of the article. Evaluation of the clinical effectiveness of the natural honey drug Metrop GP in patients with metabolically associated fatty liver disease (MAFLD). Materials and methods. A prospective randomized open multi-center study was conducted. 70 patients aged 39 to 55 years with an established diagnosis of MAFLD were included. The study group consisted of 40 patients, the control group - 30 patients. All patients received drug therapy with the hepatoprotective drug S-ademetionine. Patients in the study group were also prescribed a 10-day course of Metrop GP therapy. For a detailed assessment of the effect of the honey preparation, all subjects were divided into subgroups depending on the genesis of MAFLD: obesity/type 2 diabetes mellitus (DM2)/metabolic syndrome (MS). The dynamics of complaints was assessed. The effect of the Metrop GP on biochemical blood parameters (indicators of liver cytolysis and cholestasis, carbohydrate and lipid metabolism) and oxidative stress markers was studied. The dynamics of all indicators were assessed twice (before the study and 2 weeks after the 10-day course of treatment with Metrop GP). Non-invasive assessment of liver steatosis and fibrosis was performed using the FibroMax serological test once before the start of therapy. The study was approved by the ethics committee of Union Clinic LLC (St. Petersburg). Protocol No. 1-06/2023 dated June 6, 2023. All patients in the study group signed voluntary informed consent to conduct the study. Statistical processing of the results was carried out using SPSS 26 for Windows. Differences were considered significant at a significance level of p<0.05 (95%). Results. According to the results obtained at the end of the study, patients receiving additional Metrop GP as part of complex therapy showed a statistically significant improvement in laboratory parameters of the indices of liver cytolysis, lipid metabolism and antioxidant status, which was not achieved in the comparison subgroups. In patients with MAFLD and type 2 diabetes, a significant decrease in glucose levels was also noted during the study therapy, in contrast to the control subgroup. Patients from all study groups noted an improvement in general well-being and a decrease in dyspeptic symptoms, but without significant differences. The study drug was well tolerated. Conclusion. The addition of the hepatoprotector Metrop GP to the treatment of MAFLD leads to an improvement in lipid metabolism, normalization of the indices of liver cytolysis and the body’s antioxidant system.

метаболически ассоциированная болезнь печенигепатопротекторпрепарат медаmetabolically associated liver diseasehepatoprotectorhoney preparationReferencesYounossi Z.M., Koenig A.B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. doi: 10.1002/hep.28431.Younossi Z.M., Koenig A.B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. doi: 10.1002/hep.28431.Rong L., Zou J., Ran W., Qi X., Chen Y., Cui H., Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2023; 01 (16):13. doi: 10.3389/fendo.2022.1087260.Rong L., Zou J., Ran W., Qi X., Chen Y., Cui H., Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2023; 01 (16):13. doi: 10.3389/fendo.2022.1087260.Polyzos S.A., Kountouras J., Mantzoros C.S. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019; 92:82-97. doi: 10.1016/j.metabol.2018.11.014.Polyzos S.A., Kountouras J., Mantzoros C.S. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019; 92:82-97. doi: 10.1016/j.metabol.2018.11.014.Tanase D.M., Gosav E.M., Costea C.F., Ciocoiu M., Lacatusu C.M., Maranduca M.A., et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020; 07(31). doi: 10.1155/2020/3920196.Tanase D.M., Gosav E.M., Costea C.F., Ciocoiu M., Lacatusu C.M., Maranduca M.A., et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020; 07(31). doi: 10.1155/2020/3920196.Muzurović E., Mikhailidis D.P., Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021; 01(119). doi: 10.1016/j.metabol.2021.154770.Muzurović E., Mikhailidis D.P., Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021; 01(119). doi: 10.1016/j.metabol.2021.154770.Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016: 65(8):1038-1048. doi: 10.1016/j.metabol.2015.12.012.Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016: 65(8):1038-1048. doi: 10.1016/j.metabol.2015.12.012.Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F. et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520.Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F. et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520.Demidova T.Y., Ushanova F.O. Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review. Ter Arkh. 2023;23;95(10):888-895. (in Russ.) doi: 10.26442/00403660.2023.10.202435.Demidova T.Y., Ushanova F.O. Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review. Ter Arkh. 2023;23;95(10):888-895. (in Russ.) doi: 10.26442/00403660.2023.10.202435.Abduloeva N. Kh., Kolbasov S. Ye., Stukov A.N., Moiseenko V.M. Preclinical evaluation of the effect of metrop gp on acute toxicity and hepatotoxicity of chemotherapy. Prob in oncol. 2011; 57(1):71-74. (In Russ.)@@ Абдулоева, Н. Х., Колбасов, С. Е., Стуков, А. Н., Моисеенко, В.М. Предклиническая оценка влияния препарата Метроп ГП на острую токсичность и гепатотоксичность химиотерапии. Вопр онкол. 2011; 57(1):71-74.Abduloeva N. Kh., Kolbasov S. Ye., Stukov A.N., Moiseenko V.M. Preclinical evaluation of the effect of metrop gp on acute toxicity and hepatotoxicity of chemotherapy. Prob in oncol. 2011; 57(1):71-74. (In Russ.)@@ Абдулоева, Н. Х., Колбасов, С. Е., Стуков, А. Н., Моисеенко, В.М. Предклиническая оценка влияния препарата Метроп ГП на острую токсичность и гепатотоксичность химиотерапии. Вопр онкол. 2011; 57(1):71-74.El H.H., Di V.A., Vettor R., Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2019; 6;20(9):2215. doi: 10.3390/ijms20092215.El H.H., Di V.A., Vettor R., Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2019; 6;20(9):2215. doi: 10.3390/ijms20092215.Ghosh A.K., Vaughan D.E. PAI-1 in tissue fibrosis. J Cell Physiol. 2012;227(2):493-507. doi: 10.1002/jcp.22783.Ghosh A.K., Vaughan D.E. PAI-1 in tissue fibrosis. J Cell Physiol. 2012;227(2):493-507. doi: 10.1002/jcp.22783.Cesari M., Pahor M., Incalzi R.A. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010;28(5):72-91. doi: 10.1111/j.1755-5922.2010.00171.Cesari M., Pahor M., Incalzi R.A. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010;28(5):72-91. doi: 10.1111/j.1755-5922.2010.00171.Oishi K. Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens. 2009;31(3):208-19. doi: 10.1080/10641960902822468.Oishi K. Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens. 2009;31(3):208-19. doi: 10.1080/10641960902822468.Hamaguchi M., Takeda N., Kojima T., Ohbora A., Kato T., Sarui H. et al. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 2012;18(13):1508-16. doi: 10.3748/wjg.v18.i13.1508.Hamaguchi M., Takeda N., Kojima T., Ohbora A., Kato T., Sarui H. et al. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 2012;18(13):1508-16. doi: 10.3748/wjg.v18.i13.1508.Graham R.C., Burke A., Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastroenterol Nutr. 2009;49(4):442-449. doi: 10.1097/MPG.0b013e31819f73b4.Graham R.C., Burke A., Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastroenterol Nutr. 2009;49(4):442-449. doi: 10.1097/MPG.0b013e31819f73b4.Castro-Martínez M.G., Banderas-Lares D.Z., Ramírez-Martínez J.C., Escobedo-de la Peña J. Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome. Cir Cir. 2012;80(2):128-133.Castro-Martínez M.G., Banderas-Lares D.Z., Ramírez-Martínez J.C., Escobedo-de la Peña J. Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome. Cir Cir. 2012;80(2):128-133.Tsai C.H., Li T.C., Lin C.C. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J. 2008;101(9):900-905. doi: 10.1097/SMJ.0b013e31817e8af9.Tsai C.H., Li T.C., Lin C.C. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J. 2008;101(9):900-905. doi: 10.1097/SMJ.0b013e31817e8af9.Zhang T., Zhang C., Zhang Y., Tang F., Li H., Zhang Q. et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis. 2015;240(1):144-148. doi: 10.1016/j.atherosclerosis.2015.02.049.Zhang T., Zhang C., Zhang Y., Tang F., Li H., Zhang Q. et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis. 2015;240(1):144-148. doi: 10.1016/j.atherosclerosis.2015.02.049.Tilg H., Moschen A.R., Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32-42. doi: 10.1038/nrgastro.2016.147.Tilg H., Moschen A.R., Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32-42. doi: 10.1038/nrgastro.2016.147.Rhee E.J. Nonalcoholic fatty liver disease and diabetes: An epidemiological perspective. Endocrinol Metab (Seoul). 2019;34:226-233. doi: 10.3803/EnM.2019.34.3.226.Rhee E.J. Nonalcoholic fatty liver disease and diabetes: An epidemiological perspective. Endocrinol Metab (Seoul). 2019;34:226-233. doi: 10.3803/EnM.2019.34.3.226.En Li Cho E, Ang C.Z., Quek J., Fu C.E., Lim L.K., Heng Z.E. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138-2148. doi: 10.1136/gutjnl-2023-330110.En Li Cho E, Ang C.Z., Quek J., Fu C.E., Lim L.K., Heng Z.E. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138-2148. doi: 10.1136/gutjnl-2023-330110.Quek J., Chan K.E., Wong Z.Y., Tan C., Tan B., Lim W.H., et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X.Quek J., Chan K.E., Wong Z.Y., Tan C., Tan B., Lim W.H., et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X.Afrin S., Gasparrini M., Forbes-Hernández T.Y. Protective effects of manuka honey on LPS-treated RAW 264.7 macrophages. Part 1: Enhancement of cellular viability, regulation of cellular apoptosis and improvement of mitochondrial functionality. Food Chem Toxicol. 2018;121:203-213.Afrin S., Gasparrini M., Forbes-Hernández T.Y. Protective effects of manuka honey on LPS-treated RAW 264.7 macrophages. Part 1: Enhancement of cellular viability, regulation of cellular apoptosis and improvement of mitochondrial functionality. Food Chem Toxicol. 2018;121:203-213.Gasparrini M., Afrin S., Forbes-Hernández T.Y. Protective effects of manuka honey on LPS-treated RAW 264.7 macrophages. Part 2: Control of oxidative stress induced damage, increase of antioxidant enzyme activities and attenuation of inflammation. Food Chem Toxicol. 2018;120:578-587.Gasparrini M., Afrin S., Forbes-Hernández T.Y. Protective effects of manuka honey on LPS-treated RAW 264.7 macrophages. Part 2: Control of oxidative stress induced damage, increase of antioxidant enzyme activities and attenuation of inflammation. Food Chem Toxicol. 2018;120:578-587.Alvarez-Suarez J.M., Giampieri F., Battino M. Honey as a source of dietary antioxidants: structures, bioavailability and evidence of protective effects against human chronic diseases. Curr Med Chem. 2013;20:621-638.Alvarez-Suarez J.M., Giampieri F., Battino M. Honey as a source of dietary antioxidants: structures, bioavailability and evidence of protective effects against human chronic diseases. Curr Med Chem. 2013;20:621-638.Ahmed A., Tul-Noor Z., Lee D., Bajwah S., Ahmed Z., Zafar S., et al. Effect of honey on cardiometabolic risk factors: a systematic review and meta-analysis. Nutr Rev. 2023;81(7):758-774. doi: 10.1093/nutrit/nuac086.Ahmed A., Tul-Noor Z., Lee D., Bajwah S., Ahmed Z., Zafar S., et al. Effect of honey on cardiometabolic risk factors: a systematic review and meta-analysis. Nutr Rev. 2023;81(7):758-774. doi: 10.1093/nutrit/nuac086.Pasupuleti V.R., Arigela C.S., Gan S.H., Salam S.K.N., Krishnan K.T., Rahman N.A., et al. A Review on Oxidative Stress, Diabetic Complications, and the Roles of Honey Polyphenols. Oxid Med Cell Longev. 2020;11:1-16. doi: 10.1155/2020/8878172.Pasupuleti V.R., Arigela C.S., Gan S.H., Salam S.K.N., Krishnan K.T., Rahman N.A., et al. A Review on Oxidative Stress, Diabetic Complications, and the Roles of Honey Polyphenols. Oxid Med Cell Longev. 2020;11:1-16. doi: 10.1155/2020/8878172.

The authors declare that there are no conflicts of interest present.